Targeting AXL overcomes acquired resistance to osimertinib and other EGFR-TKIs38,39, and multiple AXL inhibitors have been developed and advanced to clinical trials involving cancer therapy to overcome drug resistance40,41. Here, EGFR is linked to cancer.